DMARDs
Sponsors
Wyeth is now a wholly owned subsidiary of Pfizer, Hoffmann-La Roche, JW Pharmaceutical, Columbia University, Mycenax Biotech Inc.
Conditions
Arthritis, PsoriaticArthritis, RheumatoidCombination With DMARDsConnective Tissue DiseasesInterstitial Lung DiseasePirfenidoneRheumatoid ArthritisSpondylitis, Ankylosing
Phase 1
Phase 3
A Study of Tocilizumab in Combination With Disease-Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Moderate to Severe Active Rheumatoid Arthritis With an Inadequate Response to DMARDs
CompletedNCT00996606
Start: 2009-10-31End: 2012-04-30Updated: 2017-06-19
Efficacy and Safety of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis
CompletedNCT01211834
Start: 2009-10-31End: 2010-10-31Target: 90Updated: 2010-11-03
To Evaluate 1 Year Extension Study of the Efficacy and Safety of Tocilizumab in Patients With Moderate to Severe Rheumatoid Arthritis
CompletedNCT01256736
Start: 2010-03-31End: 2013-11-30Updated: 2013-11-20
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of ENIA11 in Combination With DMARDs Versus DMARDs Alone in Patients With Rheumatoid Arthritis
NCT01787149
Start: 2013-09-30End: 2019-12-31Target: 98Updated: 2018-04-17
A Study to Evaluate Efficacy of Tocilizumab Administered as Monotherapy or in Combination With Methotrexate and/or Other Disease Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis (RA) Participants
CompletedNCT01941940
Start: 2013-09-05End: 2016-07-05Updated: 2017-07-11
A Study of Tocilizumab (RoActemra/Actemra) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Participants With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Biologic Agent
CompletedNCT02046603
Start: 2014-03-04End: 2016-08-04Updated: 2018-12-07
Phase 4
A Multicenter Study to Compare the Efficacy and Safety of the Combination of Etanercept and Methotrexate in Treatment of Rheumatoid Arthritis
WithdrawnNCT00783536
Start: 2008-11-30End: 2010-06-30Updated: 2022-05-09
RHYTHM (Formerly Escape II Myocardium)
CompletedNCT01548768
Start: 2011-10-10End: 2019-09-30Updated: 2020-11-27
A Long-term Safety Extension Study of Tocilizumab in Brazilian Participants With Rheumatoid Arthritis (RA) Who Completed the Studies ML21530 and MA21488
CompletedNCT01715831
Start: 2013-01-15End: 2016-06-06Updated: 2017-06-12
Rheumatoid Arthritis Memory B Cells and Abatacept
CompletedNCT03652961
Start: 2019-06-02End: 2021-09-27Updated: 2024-07-03
Optimal MTX Dose With Folic Acid Randomized Case-control Trial
NCT04066803
Start: 2018-08-01End: 2020-07-30Target: 160Updated: 2019-08-26
Immunosuppressant Combined With Pirfenidone in CTD-ILD
NCT04928586
Start: 2019-08-16End: 2025-06-01Target: 200Updated: 2023-11-18
Unknown Phase
An Observational Study of Infliximab in Participants Suffering From Ankylosing Spondylitis With Hip Involvement
TerminatedNCT02293681
Start: 2015-04-10End: 2017-05-31Updated: 2017-11-01
PANLAR's Latin American Registry of Rheumatic Patients Treated With Jak Inhibitors
NCT04821206
Start: 2021-03-01End: 2024-07-01Target: 3000Updated: 2021-03-29
Cortisol Circadian Rhythm in Patients With RA
NCT05671627
Start: 2022-02-02End: 2023-06-30Target: 50Updated: 2023-01-04